Today, we update IMV Inc. (IMV), formerly ImmunoVaccine, which we last featured here in mid-January, to highlight insider buying.
Shares set a 52-week high of $9.49 on June 1 ahead of IMV’s anticipated presentation at the American Society for Clinical Oncology’s annual meeting. The stock has dropped nearly 10 per cent following the presentation.
However, insider indications suggest the selling may be premature. Insiders, including the chairman, CEO and CFO, spent a combined $111,505 picking up shares in the public market last Tuesday.
Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.
Chart reflects public-market transactions of common shares or unit trusts by company officers and directors.